Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the impact on progression-free survival (PFS) with
the combination carboplatin - pembrolizumab in patients with CTC (circulating tumor cells)
positive, HER2 negative metastatic breast cancer previously treated with anthracyclines and
taxanes. Previous studies have indicated that recurrent breast cancers are more resistant to
chemotherapy and maybe associated with a weak immune system. This study is investigating the
use of an immune therapy drug, pembrolizumab, that has the ability to restore the capacity of
controlling and killing cancer cells of an important component of your immune system called
T-cells. Pembrolizumab has been found effective in other types of cancer and has already been
approved by FDA for those indications, but the efficacy in breast cancer is still unknown. In
this study, pembrolizumab will be combined with chemotherapy to increase the cancer cell
killing. There is no control or placebo treatment in this study.
Phase:
Phase 2
Details
Lead Sponsor:
Northwestern University
Collaborators:
Merck Sharp & Dohme Corp. National Cancer Institute (NCI)